Drugs / 68Ga-FAP-CHX
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05515783 | May 2022 → May 2024 | neoplasm | First Affiliated Hospital of Fujian Medical University | Unknown | No outcome recorded |
| Phase 1/2 | NCT05506566 | May 2022 → May 2025 | neoplasm | First Affiliated Hospital of Fujian Medical University | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 68Ga-FAP-CHX | “68Ga-FAP-CHX, the dose will be 0.05 (mCi / kg) given intravenously at a single time prior to imaging.” NCT05515783 ↗1“68Ga-FAP-CHX is promising as an excellent imaging agent applicable to various cancers” NCT05506566 ↗ |
| Modality | Diagnostic / imaging agent | “68Ga-FAP-CHX is promising as an excellent imaging agent applicable to various cancers” NCT05506566 ↗ |
| Route | Intravenous | “given intravenously at a single time prior to imaging” NCT05506566 ↗ |
| Target | FAP | “As an emerging molecule targeting FAP” NCT05506566 ↗ |